DCH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dauch Corp (DCH) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple Buy ratings and price targets significantly above the current price, positive insider activity, and promising synergies from its recent acquisition. Despite some technical indicators showing neutral signals, the long-term growth potential and favorable sentiment make it a suitable investment.
The MACD histogram is negative (-0.164) and contracting, indicating a bearish trend. RSI is neutral at 60.043, and moving averages are converging, showing no clear directional trend. The stock is trading near its resistance level (R1: 5.9), with support at 5.182.
Insider confidence: Director David B. Walker purchased 35,000 shares, signaling optimism about the company's future.
Analysts have reinstated or upgraded Buy ratings with price targets ranging from $8 to $10.35, citing valuation support, merger synergies, and long-term opportunities.
The acquisition of Dowlais Group is expected to generate $300 million in annual synergies, enhancing the company's competitive position.
Recent financials show a net loss of $73 million, although this is a significant YoY improvement.
Gross margin dropped by 9.93% YoY, indicating potential cost pressures.
The stock's price has declined in pre-market and regular trading (-0.83% and -1.50%, respectively), reflecting short-term weakness.
In Q4 2025, revenue increased slightly by 0.22% YoY to $1.38 billion. Net income improved significantly by 453.03% YoY to -$73 million, and EPS increased by 454.55% YoY to -0.61. However, gross margin declined by 9.93% YoY to 8.71%, indicating some operational challenges.
Analysts are bullish on Dauch Corp. BofA, Deutsche Bank, and Jefferies have all issued Buy ratings with price targets ranging from $8 to $10.35, citing valuation support, merger synergies, and strategic alignment. RBC Capital maintains an Outperform rating with a slightly reduced price target of $10 due to accounting adjustments related to the Dowlais acquisition.
